Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1

Interventions

Rituximab 3Cyclophosphamide 3zanubrutinib 2fludarabine 2tafasitamab 1resiniferatoxin 1obinutuzumab 1duvelisib 1Vincristine 1Vancomycin 1Thiotepa 1Surveys and Questionnaires 1Radiotherapy 1Prednisone 1Prednisolone 1PTH2 protein, human 1Observation 1Neuropsychological Tests 1Methotrexate 1Magnetic Resonance Spectroscopy 1Lisaftoclax 1Interleukin-2 1Injections, Subcutaneous 1Homoharringtonine 1Glucocorticoids 1Doxorubicin 1Dexamethasone 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Lymphoma, Non-Hodgkin × PTH2 protein, human × Clear all
NCT07159906 2025-09-08

Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

First Affiliated Hospital of Zhejiang University

Phase 1/2 Not yet recruiting
62 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡